On October 1, 2026 BostonGene, developer of the leading AI model for tumor and immune biology, reported that Nathan Fowler, MD, Chief Medical Officer, will participate in the 2nd Annual Global Cancer Research & Innovation Symposium, taking place October 5–6, 2026, in New York City. Dr. Fowler will join leaders from across the oncology ecosystem for a discussion on how multimodal data can be integrated to improve drug discovery and clinical development.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
As oncology therapies become more precise, development teams increasingly need to understand how genomic alterations, tumor states, and immune biology interact within individual patients. The panel, titled "Multi-Omics: One Size Does Not Fit All!," will examine how whole genome sequencing, single-cell analysis, spatial transcriptomics, and other advanced modalities can be combined to explain therapeutic response and resistance, identify biologically defined patient populations, and guide trial design and therapeutic strategy.
"The objective is not simply to generate more data. It is to understand why a therapy works in one patient and not another, and then translate that biology into decisions that improve clinical development," said Nathan Fowler, MD, Chief Medical Officer at BostonGene. "By placing each patient and drug into a broader biological context, we can identify mechanisms of response and resistance, define the patients most likely to benefit, and help development teams make better decisions about biomarkers, trial design, and therapeutic strategy. I look forward to discussing how these capabilities can help move precision oncology from biological insight to clinical action."
Session Details:
Title: Multi-Omics: One Size Does Not Fit All!
Moderator:
Stan Skrzypczak, MS, MBA, Managing Partner, 5 Prime Life Science Consulting
Featured Panelists:
Nathan Fowler, MD, Chief Medical Officer, BostonGene
Serge Saxonov, PhD, CEO and Co-Founder, 10x Genomics
Elli Papaemmanuil, PhD, Global Vice President, Oncology, Translational Medicine, Genentech
Prathesh Sathyan, PhD, Head of AMR Oncology and Medical Affairs, Illumina
For more information on the conference or to view the full agenda, visit avbcc.org/gcris.
(Press release, BostonGene, OCT 1, 2026, View Source [SID1234671229])